跳到正文
EMA 官方医药监管信息·精选AI 评分76

EMA 发布《胃肠道相互作用研究指南》草案并公开征求意见

Draft guideline on the investigation of interactions in the gastrointestinal tract

AI 导读

CHMP 于 2026 年 6 月 15 日通过 EMA《胃肠道相互作用研究指南》草案(EMA/136069/2026)并放行公开征求意见,征求意见自 2026 年 9 月 11 日开始,截止 2026 年 12 月 31 日。

推荐理由

草案列出食物、胃内pH与抑酸剂、辅料等因素影响吸收时的研究与结果解读建议,可供定位需核对的章节。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

1   15 June 2026
2   EMA/136069/2026
3   Committee on Medicines for Human Use (CHMP)




4   Guideline on the investigation of interactions in the
5   gastrointestinal tract
6   Draft


7
8
9


      Draft agreed by Methodology Working Party (MWP), Quality
                                                                                                                       March 2026
      Working Party has been consulted

      Adopted by CHMP for release for consultation                                                                    15 June 2026

      Start of public consultation                                                                         11 September 2026

      End of consultation (deadline for comments)                                                           31 December 2026

10
11
      Comments should be provided using this EUSurvey form. For any technical issues, please contact
      the EUSurvey Support.

12
      Keywords                    Gastrointestinal tract, interaction, food, gastric pH, formulation
13




     Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
     Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
     Send us a question Go to www.ema.europa.eu/contact     Telephone +31 (0)88 781 6000       An agency of the European Union


                   © European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

第 2 页

14   Guideline on the investigation of interactions in the
15   gastrointestinal tract
16   Table of contents
17   1. Introduction (background) ...................................................................... 3
18   2. Scope....................................................................................................... 3
19   3. Legal basis and relevant guidelines ......................................................... 4
20   4. Investigation of interactions in the gastrointestinal tract ....................... 4
21   4.1. Effects of food intake on the pharmacokinetics of the investigational drug ................... 4
22   4.2. Gastric pH: drug-drug interaction with acid reducing agent ........................................ 6
23   4.3. Gastric emptying or intestinal motility ..................................................................... 9
24   4.4. Excipients ............................................................................................................ 9
25   4.5. Complex formation ............................................................................................. 10
26   4.6. Enterohepatic recirculation .................................................................................. 10

27   5. Reporting and interpretation ................................................................. 11
28   6. Risk assessment and management ........................................................ 11
29

30




     Guideline on the investigation of interactions in the gastrointestinal tract
     EMA/136069/2026                                                                                                     Page 2/12

第 3 页

31   Executive summary
32
33   This guideline provides recommendations with regards to situations where the absorption of a drug
34   from a medicinal product is altered by extrinsic factors in the gastrointestinal tract. Recommendations
35   are provided on design, conduct and interpretation of in vitro and clinical absorption-related interaction
36   studies. Treatment recommendations based on the clinical relevance of the interactions and the
37   possibility to make dose adjustments or treatment monitoring are addressed.


38   1. Introduction (background)
39   Patients are often prescribed more than one medicinal product and interactions between the medicines
40   (drug-drug interactions (DDI)), sometimes lead to adverse events or alternatively can partially or
41   completely negate treatment efficacy. The ageing European population, in which polypharmacy is more
42   frequent, increases the likelihood of such interactions. The aim of interaction studies performed on new
43   medicinal products is to gain knowledge of how the new medicinal product affects the safety and
44   efficacy of other medicinal products and vice versa.

45   Interactions in the upper gastrointestinal tract can result from extrinsic factors affecting the absorption
46   of orally administered medicinal products. In addition to gastric pH changes, food intake, product
47   formulation and formation of complexes or chelates can affect the intestinal absorption of a drug and
48   this may have consequences for efficacy or safety.

49   On 30 November 2024, ICH M12 Guideline on drug interaction studies (EMA/CHMP/ICH/652460/2022)
50   formally superseded EMA Guideline on the investigation of drug interactions Revision 1
51   (CPMP/EWP/560/95/Rev. 1 Corr. 2**) which had been in effect since 1 January 2013. ICH M12 focuses
52   on pharmacokinetic drug interactions mediated by metabolic enzymes and drug transporters and as
53   such, does not address drug interactions mediated in the upper gastrointestinal part to the same
54   extent that the EMA guideline did. However, the latter interactions are an important component of
55   evaluating a new drug’s interaction potential.

56   This document, therefore, describes the investigation of absorption related interactions affecting the
57   investigational drug through extrinsic factors in the gastrointestinal tract. This includes advice on study
58   design, presentation of study results and translation of these results to treatment recommendations in
59   the labelling of the medicinal product.


60   2. Scope
61   The scope of this guideline is to provide advice and recommendations on how to evaluate the
62   absorption interaction potential of a new medicinal product in the gastrointestinal tract e.g. due to
63   gastric pH change, formation of complexes or chelates and investigation of food effect. The
64   recommendations may also be applicable to changes in product formulations or method of
65   administration.

66        •    The guideline mostly describes interactions with the new medicinal product as an object,
67             however, for some aspects (e.g. effect on gastric emptying, effect of excipients) the potential
68             influence of the new medicinal product on the exposure of another medicinal product is also
69             addressed.

70        •    The guideline primarily applies to systemically acting active substances that need to be
71             absorbed to exert their pharmacological effect. Many of the recommendations can also be
72             considered for medicinal products that are locally applied and locally acting in the



     Guideline on the investigation of interactions in the gastrointestinal tract
     EMA/136069/2026                                                                                      Page 3/12

第 4 页

73             gastrointestinal tract, as many of the interactions described are also likely to affect the
74             concentration of the active substance in the gastrointestinal tract.

75        •    The guideline covers mainly orally administered medicinal products, but some aspects (e.g.
76             effect of gastric emptying and motility) may be applicable also to other routes of
77             administration.

78        •    Drug interactions mediated by metabolic enzymes and drug transporters in the intestinal cells
79             are not included in this guideline as these are covered in ICH M12.


80   3. Legal basis and relevant guidelines
81
82   This guideline should be read in conjunction with the introduction and general principles (4) of the
83   Annex I to Directive 2001/83/EC as amended, as well as European and ICH guidelines for conducting
84   clinical trials, including

85        –    ICH M12 Guideline on drug interaction studies (EMA/CHMP/ICH/652460/2022)
86        –    EC SmPC Guideline (London, 20 November 2008)

87        –    Guideline on the requirements to the chemical and pharmaceutical quality documentation
88             concerning investigational medicinal products in clinical trials (EMA/CHMP/QWP/545525/2017
89             Rev. 2)

90        –    Guideline on quality of oral modified release products (EMA/CHMP/QWP/428693/2013)
91        –    Guideline on the clinical evaluation of modified release dosage forms (EMA/CHMP/EWP/280/96
92             Rev1)

93        –    Guideline on pharmaceutical development of medicines for paediatric use
94             EMA/CHMP/QWP/805880/2012 Rev. 2
95        –    Reflection paper on the pharmaceutical development of medicines for use in the older
96             population EMA/CHMP/QWP/292439/2017


97     4. Investigation of interactions in the gastrointestinal tract

98   The investigation of absorption interactions serves to identify situations where the solubility,
99   dissolution or absorption of a drug is altered by extrinsic factors leading to a change in the rate and/or
100   extent of drug absorption to an extent which may affect the efficacy or safety of the drug. Studies of
101   the effect of food, increased gastrointestinal pH, complex binding, gastrointestinal motility, and
102   modified intestinal active transport should be considered.

103   General principles regarding DDI study design and evaluation as well as reporting and interpretation of
104   clinical DDI results presented in ICH M12 are generally applicable also for the evaluation of interactions
105   in the gastrointestinal tract.

106   4.1. Effects of food intake on the pharmacokinetics of the investigational
107   drug

108   Food changes temporarily the physiological conditions in the human gastrointestinal tract by increasing
109   the gastric pH, slowing the gastric emptying, increasing luminal bile salts and enzymes and increasing
110   intestinal and hepatic perfusion. In this way, food may affect the rate and extent of absorption of a
111   drug, e.g. by slower release from the stomach, by changes in solubility, in contact with enterocytes
112   and in first pass-effect.

113   The effect of food intake on the rate and extent of absorption of the active substance of an orally
114   administered medicinal product should be investigated as early as possible during drug development to
115   optimise dose finding and to ensure appropriate food recommendations in phase 3 clinical studies. In

      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                         Page 4/12

第 5 页

116   general, intake of a medicinal product in relation to meal times should aim at minimising variability of
117   exposure and obtaining safe and efficacious exposure, without causing unnecessary restrictions for the
118   patient. Another common reason for recommending intake with food is gastrointestinal tolerability
119   issues.

120   Although it is recommended to evaluate the food effect early in clinical development, the food effect of
121   the commercial formulation also needs to be addressed if formulation changes have been made. The
122   food effect of the commercial formulation should be investigated in a food effect study or it needs to be
123   adequately justified that a similar food effect is expected e.g. based on the nature of the formulation
124   changes performed, the evaluated food effect of earlier clinical development formulations and the
125   solubility of the drug and bioavailability of the active substance.

126   In general, the bioavailability of the active substance of a new medicinal product should be compared
127   under the most extreme situations i.e., in fasted state and with a high-fat meal. When a clinically
128   significant effect of a high-fat meal is found, further food interaction studies may be needed (see
129   section on Study design). On the other hand, if there is no clinically relevant effect of a high-fat meal
130   on the absorption of the active substance compared to fasted conditions, it can generally be assumed
131   that other types of meals will not affect the absorption of the active substance.
132   Study design

133   In a standard cross-over food effect study, a single dose of the investigational medicinal product is
134   administered with 150-250 ml of water after a 10-hour fasting period either without food, or 30
135   minutes after intake of a meal has started. Thereafter, the subjects should refrain from food for at
136   least 4 hours after drug administration and all food intakes should be standardised for at least 12
137   hours post-dose. The recommended composition of a high fat meal and a moderate fat/calorie meal
138   are described below. In case a single dose study cannot be performed in healthy subjects or patients, a
139   multiple dose, steady-state study with administration of doses of the medicinal product under fasting
140   and fed conditions, respectively, may be satisfactory.

141   When a clinically significant food effect is found (section 5), further food interaction studies may be
142   warranted to support recommendations regarding type of food and the timing of drug administration in
143   relation to food intake.

144   Dose

145   Usually, a therapeutic dose is evaluated in the food effect study. Any dose in the therapeutic dose
146   range can be selected for the food effect study when the pharmacokinetics is dose proportional. The
147   results obtained with one dose can be extrapolated to the other doses. If the pharmacokinetics is non-
148   linear with less than dose-proportional increases in the AUC or Cmax when increasing the dose, it is
149   recommended to investigate the effect of food on both the highest and lowest doses of the therapeutic
150   range. If the pharmacokinetics is non-linear with larger than dose-proportional increases, studying the
151   food effect with the highest dose is generally sufficient.

152   Strengths

153   For the food effect study the clinical dose range rather than the strengths are considered. In rare cases
154   that the various strengths deviate markedly in composition, food effect of more than one strength may
155   need to be investigated. In such case, excipients, availability of pharmacokinetic data with various
156   strengths and whether a food effect has been observed on other strength(s), solubility of the drug and
157   linearity of the pharmacokinetics should be considered. The strengths that deviate most in composition
158   should be selected if an additional food effect study is deemed necessary.

159   Standardised meals



      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                    Page 5/12

第 6 页

160   The high fat meal should contain 800-1000 kcal with 500-600 kcal from fat and 250 kcal from
161   carbohydrates. A standard test high fat meal can be composed of: two eggs fried in butter, two strips
162   of bacon, two slices of toast with butter, 120 ml of hash brown potatoes and 240 ml of whole milk.
163   Substitutions in this test meal can be made as long as the meal provides similar amounts of calories
164   from protein, carbohydrate, and fat and has comparable meal volume and viscosity.
165   A moderate fat/calorie meal can contain approximately 400-500 kcal with fat contributing to ca. 150
166   kcal.

167   Other considerations

168   When the effect of food cannot be studied in healthy subjects but has to be studied in patients, the
169   type of meal recommended for the target patient population or a moderate-fat meal can be
170   considered.

171   If physicochemical properties of the drug and in vitro data indicate that complex binding with bivalent
172   cations might become an issue in vivo, the need for a food interaction study with a dairy food product
173   (calcium-rich) should be considered. This should be addressed especially when the medicinal product is
174   intended for newborns and infants whose diet is different than adults (e.g. 100% milk-based in
175   newborns). See also section 4.5.

176   Some foods or beverages (e.g. grapefruit juice, coffee) have the potential to inhibit or induce intestinal
177   enzymes or transporters and thus can affect the oral bioavailability of an investigational drug. When
178   the mechanism of such interaction is known, interactions with this type of food are usually not
179   investigated in a clinical drug interaction study, but avoidance of this type of food might be
180   recommended in the product information. Consumption of these products prior to and during a food
181   effect or drug drug interaction study is usually excluded or limited.

182   For modified release formulations, advice regarding the investigation of the effect of food or alcohol on
183   drug release are given in guidelines specific for these formulations (see EMA Guideline on
184   pharmacokinetic and clinical evaluation of modified-release dosage forms (EMA/CHMP/EWP/280/96
185   Rev1)).

186   In many cases, it is desirable to be able to administer an oral formulation in alternative ways to
187   patients with difficulties to swallow. For example, a drug product could be opened, crushed,
188   disintegrated in liquid or sprinkled on soft food or administered via a feeding tube. In order to include
189   information on these alternative ways of handling the medicinal product in the Summary of Product
190   Characteristics, supporting data is usually needed. Generally, an in vivo relative bioavailability study is
191   expected unless justified. A justification may include a discussion on Biopharmaceutics Classification
192   System-class, dissolution rate of drug product or available bioequivalence data on other oral
193   formulations and the therapeutic window. The bioavailability study should reflect the intended
194   administration conditions for both the crushed/opened and intact formulation. In addition, quality data
195   should be provided, e.g. to demonstrate a lack of physicochemical interactions between soft food or
196   liquid and the drug product (Guideline on the requirements to the chemical and pharmaceutical quality
197   documentation concerning investigational medicinal products in clinical trials,
198   EMA/CHMP/QWP/545525/2017 Rev. 2; Guideline on pharmaceutical development of medicines for
199   paediatric use, EMA/CHMP/QWP/805880/2012 Rev. 2; Reflection paper on the pharmaceutical
200   development of medicines for use in the older population, EMA/CHMP/QWP/292439/2017).

201   4.2. Gastric pH: drug-drug interaction with acid reducing agent

202   Drugs with in vitro solubility that is markedly pH dependent within the physiological pH range (between
203   1.2 and 6.8), may have their absorption affected by concomitant administration of drugs which change
204   the gastrointestinal pH. If in vitro data indicate that pH-dependent solubility may impact the absorption

      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                    Page 6/12

第 7 页

205   of the investigational drug, an in vivo DDI study should generally be performed with an appropriate
206   acid reducing agent (ARA). The potential for a pH-dependent DDI should preferably be evaluated early
207   in clinical development to ensure subsequent efficacy and safety for patients.

208   Drugs at the highest risk for a clinically relevant interaction with ARAs are weak-bases with low
209   aqueous intrinsic solubility, where increased gastric pH (i.e. pH>4) can decrease solubility and
210   absorption, potentially leading to loss of efficacy.

211   Absorption of weak-acidic drugs with low solubility at low pH (~1.2) and increased solubility at higher
212   pH may also theoretically be affected by co-administration with an ARA. However, there are currently
213   limited data and the observed effects are generally minor and not considered clinically significant under
214   most circumstances. Therefore, for weak acids the need for a clinical DDI study should be evaluated
215   based on the drug safety profile.

216   In general, if the drug has pH dependent solubility but exhibits high solubility across the physiological
217   pH range, a DDI study with an ARA is not required. If the tested drug is a modified release formulation
218   with a pH-sensitive release mechanism, gastrointestinal pH modification may affect the drug release
219   and consequently the drug absorption. Further recommendations on in vitro and in vivo investigations
220   to conduct are provided in EMA Guideline on quality of oral modified release products
221   (EMA/CHMP/QWP/428693/2013) and EMA Guideline on the pharmacokinetic and clinical evaluation of
222   modified release dosage forms (EMA/CHMP/EWP/280/96 Rev1), respectively.

223   Considerations for study design

224   An in vivo DDI study quantitatively determines the DDI potential of the investigated drug with an ARA.
225   The aim of the study could be either to evaluate the worst-case scenario, or to support alternative
226   dosing regimens to avoid clinical drug-drug interactions. If the purpose of the study is to evaluate the
227   worst-case magnitude of a DDI, the investigated drug and the ARA should be administered when the
228   ARA effects are most pronounced. On the other hand, if the purpose is to support an alternative dosing
229   regimen to avoid clinical DDI, then staggered administration should be applied.

230   Generally, the ARA should be administered at the highest recommended dose under therapeutic
231   conditions with a sufficiently long duration to reach the maximal pharmacodynamic effect. Usually,
232   single dose administration of the investigational drug is adequate unless the absorption is modified
233   following repeated administrations, or if the study is conducted in patients in whom a single
234   administration is not adequate.

235   The interaction study of the investigational drug with an ARA should be conducted under the prandial
236   conditions consistent with the intended clinical use. For investigational drugs intended to be
237   administered in a fasted state, drug interaction studies should thus be conducted under fasted
238   conditions. Conversely, if the investigational drug is intended for administration with food, studies
239   should be conducted under fed conditions using a moderate fat/calorie meal to align with clinical
240   practice.

241   If the investigational drug is to be administered regardless of food intake, studies should still be
242   conducted under fasted conditions, as this represents the worst-case scenario for absorption. For
243   several drugs the impact of ARAs on the absorption is considerably less under fed conditions compared
244   to fasted conditions. When there is a clinically relevant effect of an ARA on the absorption of an
245   investigational drug under fasted conditions and the drug can be administered with and without a
246   meal, applicants are encouraged to evaluate the effect of ARAs also under fed conditions.

247   Selection of the ARAs to be used in the in vivo study should consider the aim of the study, the ARA's
248   properties, including its onset and duration of action, the extent of acid secretion inhibition, and the



      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                      Page 7/12

第 8 页

249   enzymes involved in its metabolism. Specific considerations for the common pharmacological classes
250   are provided below.

251        –    Proton pump inhibitors

252   Proton pump inhibitors (PPIs) are the most commonly prescribed ARAs. PPIs irreversibly bind to H+-K+-
253   ATPase thereby reducing gastric acid production. PPI’s effect on gastric pH is dose-dependent and is
254   more pronounced and lasts longer than the effect of H2 antagonists. The baseline gastric acid
255   secretory capacity may not be restored for up to 24–48 h after discontinuing PPI therapy.

256   In the DDI study, the PPI should be administered for at least 4 days to reach pharmacodynamic steady
257   state. The magnitude of increase of gastric pH and its duration over 24 hours is dependent on the
258   selected PPI and the dose applied. Choice of PPI, dose and timing of dosing between PPI and the
259   medicinal product should be justified.

260   Additionally, if the investigational drug is a CYP2C19 substrate, it should be considered that many
261   proton pump inhibitors (e.g. omeprazole) are CYP2C19 inhibitors.

262        –    H2 antagonists

263   H2 antagonists compete with histamine for the H2 receptor. In a DDI study, H2 antagonists should be
264   administered at the therapeutic dosing regimen. Given the rapid onset of action, usually gastric pH is
265   increased 2h post-dosing, and the effect lasts up to approximately 12h, multiple administration is not
266   required to obtain a maximal increase in gastric pH. Hence, a single dose, cross-over study of the new
267   medicinal product with and without H2 antagonist with justified timing between administration of the
268   medicinal product and the H2 antagonist is adequate.

269   It should be noted that some H2 antagonists are weak inhibitors of some CYPs isoforms, and/or
270   transporters.

271        –    Antacids

272   Antacids are cationic bases that increase intragastric pH by neutralisation of local acidity. Their onset
273   of action is fast but also short-lived. The timing of the antacid and the investigational drug
274   administrations should be carefully considered.

275   Given the salt nature of antacids, possible complex binding with the investigational drug might occur
276   depending on the physicochemical properties of the investigational product.

277   Study results interpretation

278   DDI study results obtained with an ARA may only be extrapolated within the same pharmacological
279   class. However, if an adequate DDI study conducted with a PPI demonstrates the absence of a
280   clinically significant interaction, extrapolation of this finding to the other ARA classes is considered
281   acceptable. Given the pronounced and prolonged effect of PPIs on gastric pH elevation, well-performed
282   PPI studies are regarded as a worst-case scenario for assessing potential interactions with ARAs.

283   In cases where a study with a PPI indicates a clinically significant alteration in the exposure of the
284   investigated drug, DDI mitigation strategies are encouraged. Further investigation with H2 antagonists
285   or antacids is recommended to support alternative dosing regimens to potentially avoid clinical drug-
286   drug interactions.

287   Modelling and Simulation approach

288   In some cases, the population pharmacokinetic modelling analyses of data from the pivotal clinical
289   trials can be used to gain some information on a potential ARA-interaction, provided that a sufficient
290   number of subjects have received ARAs in the clinical trials. Information on duration of ARA


      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                      Page 8/12

第 9 页

291   administration should be documented and preferably also information on dose, time of administration
292   as well as prandial state. Whereas time of administration of a PPI might be less critical due to its
293   prolonged effect, inclusion of antacids and H2 antagonists as covariates in the population
294   pharmacokinetic analysis is only possible when timing of administration of the drug in relation to intake
295   of ARAs is well documented. The analysis should preferably be pre-specified, and a stratified covariate
296   analysis, based on the pharmacological class of ARA, on the effect of the ARA on the pharmacokinetics
297   of the drug is performed. Pharmacokinetics of subjects without co-medication with any ARA should be
298   compared to the individual ARA pharmacological classes. ARAs of the different pharmacological classes
299   should not be pooled.

300   Physiologically based pharmacokinetic modelling or semi-mechanistic absorption models may also be
301   used in some cases, provided that the model has been adequately qualified for the appropriate context
302   of use (see ICH M15 Guideline on general principles for model-informed drug development
303   (EMA/CHMP/ICH/496426/2024); Guideline on the reporting of physiologically based pharmacokinetic
304   (PBPK) modelling and simulation (EMA/CHMP/458101/2016)).

305   4.3. Gastric emptying or intestinal motility

306   Certain drugs (e.g. opioids, GLP-1 receptor agonists) and excipients (e.g. polyols) are known to affect
307   gastric emptying or intestinal motility and may thus affect the rate and extent of absorption of
308   concomitantly administered drugs. This is particularly relevant for drugs with a narrow therapeutic
309   window or for medicinal products for whose early onset of action is of clinical relevance. It may also be
310   relevant for modified release formulations or drugs with a limited physiological absorption window,
311   marked permeability limited absorption or significant Cmax related effects.

312   If the investigational drug affects the gastrointestinal motility or gastric emptying, the interaction
313   potential should be considered and, if indicated, the effect should be studied on relevant drugs (e.g.
314   paracetamol as probe substrate in case of effects on gastric emptying). It should be noted that effects
315   on the gastrointestinal motility are often due to a systemic effect and may be caused also by
316   parenterally administered medicinal products e.g. GLP-1 receptor agonists.

317   4.4. Excipients

318   Excipients, such as diluents, fillers, binders, lubricants, coatings, solvents, flavouring and dyes, are
319   often inert substances used to manufacture a reproducible, stable drug product. However, some
320   excipients can significantly influence the absorption characteristics of drugs through mechanisms such
321   as an impact on solubility, dissolution or stability, a change in intestinal permeability (including
322   transporters), modulation of the gastrointestinal motility, or site-specific delivery of a drug.

323   Effect of an excipient on concomitantly used medicinal products

324   Widely used excipients such as macrogols, polysorbates, cyclodextrins, sodium laurilsulfate,
325   macrogolglycerol ricinoleate and tocofersolan, are used to improve the solubility and dissolution of a
326   drug and thus improve absorption of the drug. Whilst improving the absorption of the drug of interest,
327   the excipient may inadvertently impact the drug absorption of concomitantly administered medicinal
328   products. Also sugar-alcohols such as mannitol and sorbitol, which are frequently used as sweeteners
329   to mask poor taste of the active substance, are known to affect the absorption of drugs (see section
330   4.3). The risk that a given excipient will influence the absorption of another co-administered drug
331   should be assessed mechanistically by considering:

332   • the amount of excipient used,

333   • the mechanism by which the excipient may affect absorption,

      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                        Page 9/12

第 10 页

334   • absorption properties (rate, extent and mechanism of absorption of the concomitantly administered
335   drug).

336   For most commonly used excipients, literature data describing the potential impact on the absorption
337   of drugs is expected to be sufficient to provide relevant information in the Summary of Product
338   Characteristics, when needed. However, if the risk of a clinically relevant effect of the excipient on the
339   absorption of concomitantly used drugs cannot be estimated using other data, an in vivo interaction
340   study is recommended.

341   Distinct function of excipient to increase absorption of the investigational drug

342   Sometimes an excipient is claimed to have a more distinct function on the absorption of a drug
343   resulting in a specific formulation characteristic, e.g. salcaprozate sodium as absorption enhancer for
344   peptides or tartaric acid to create a micro-acid environment in the stomach while the gastric pH is
345   increased by ARAs. The mechanism by which such an excipient is expected to enhance the
346   bioavailability of the investigational drug should be discussed and a comparative pharmacokinetic
347   study with and without the excipient is recommended to demonstrate the impact of the excipient on
348   the bioavailability of the drug. The design of the study with regard to the use of fasting and/or fed
349   conditions depends on the dosing instructions in the Summary of Product Characteristics.


350   4.5. Complex formation

351   Other mechanisms of interference with drug absorption, such as complex binding should also be
352   considered. For example, simultaneous administration of multivalent cation-containing drugs and
353   mineral supplements (e.g. calcium, magnesium, aluminium, iron) or polymeric phosphate binders (e.g.
354   sevelamer or lanthanum carbonate), reduces the absorption of many orally administered drugs
355   including some antibiotics.

356   If physicochemical properties of the drug and in vitro data indicate that complex binding might become
357   an issue in vivo, an in vivo interaction study should be considered. Also, a time interval between
358   administration of the two medicinal products so that the interaction is minimal or not present should be
359   proposed based on in vivo data or other justification.


360   4.6. Enterohepatic recirculation

361   Bioavailability of drugs that undergo enterohepatic recirculation may be reduced in situations when the
362   enterohepatic recirculation is affected. For example, bile acid sequestrants can decrease the absorption
363   of drugs that undergo hepatic recirculation by mechanisms such as complex formation or decreased
364   solubility. Additionally, several oral antibiotics may interfere with the enterohepatic recirculation of
365   drugs excreted in the bile as glucuronide-metabolites. These metabolites are further deglucuronidated
366   by β-glucuronidase enzymes present in intestinal bacteria allowing the parent drug to be reabsorbed
367   into the circulation. Antibiotics, which kill those bacteria, prevent the glucuronide-metabolite to be
368   converted back to the parent drug, and in this way lower the bioavailability of the parent drug.

369   For drugs for which significant enterohepatic recirculation is suspected (e.g. substantial secondary
370   peaks in the pharmacokinetic curve, bile excretion in animals...etc), clinical DDI interaction studies
371   should be conducted on a case-by-case basis, considering contribution of enterohepatic recirculation to
372   the oral bioavailability, the therapeutic window as well as the likelihood of co-administration of the
373   medicine with bile acid sequestrants or/and oral antibiotics.




      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                    Page 10/12

第 11 页

374     5. Reporting and interpretation
375   For the food or drug interaction studies, the following exposure measures should be determined for
376   each subject: AUC0-t, Cmax, and time to Cmax (tmax). These parameters for metabolites, when
377   measured, should also be presented. Pharmacokinetic results of the interaction studies should be
378   reported as the geometric mean ratio of the observed pharmacokinetic exposure measures with and
379   without food / the precipitant drug and the associated 90 percent confidence interval. Measures of the
380   observed variability of the interaction, such as the range of AUC or Cmax ratios for individuals in a
381   cross-over study, should be reported.
382   Results from pharmacodynamic endpoints, whenever available, should be reported and summarised.
383
384   The results of the interaction study should be discussed considering the therapeutic window (no-effect
385   boundaries) of the medicinal product (ICH M12 guideline on drug interaction studies, section 5.3.1).

386   If there is no clinically relevant food effect but the medicinal product is to be administered under
387   certain fasted or fed conditions for tolerability or pharmacodynamic reasons, the reason for the food
388   restriction should be explicitly indicated in the Summary of Product Characteristics section 4.2 ‘Method
389   of administration’.

390


391     6. Risk assessment and management
392   DDI management strategies such as interaction prevention and risk minimisation strategies, should be
393   based on the assessment of interaction risk from altered drug absorption, with relevant principles from
394   ICH M12 applying.

395   Since the interactions described in this guideline involve absorption mediated interactions, these
396   interactions are limited by the time span in the gastrointestinal tract. Many interactions could be
397   mitigated by staggering the administration between the two medicinal products. However, for an
398   interaction with the long acting proton pump inhibitors as precipitant, this is usually not an option.

399   The risk of adverse events and reduced efficacy should be discussed in the registration dossier for a
400   patient erroneously taking the medicinal product occasionally under the not-recommended food
401   conditions when there is a clinical relevant food effect and the medicinal product should be
402   administered either under fasted or fed conditions. If there is considered a risk, risk minimisation and
403   communication of risks should be applied.

404   In general, DDI management strategies should ensure that drug concentrations of the investigational
405   drug fall within the no-effect boundaries. The risk assessment and development of risk minimization
406   strategies should consider the following factors:

407        –    The exposure-response relationships for safety and efficacy;

408        –    The variability of the observed DDI data, if available;

409        –    The expected duration of concomitant medicinal product use (e.g., acute, short-term, or
410             chronic use of one or both medicinal products);

411        –    The anticipated timing of the introduction of the concomitant medication;

412        –    The mechanism of the DDI;

413        –    The availability of monitoring parameters (e.g., therapeutic drug monitoring, laboratory tests);



      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                  Page 11/12

第 12 页

414        –    The ability to interrupt the investigational medicinal product or concomitant interacting
415             medication and the availability of other therapeutic options for either drug;

416        –    The clinical importance of the relevant adverse outcome relative to the clinical benefit of the
417             medicinal products;

418   After considering the items above, DDI management strategies can include the following:

419   -         Contraindication or avoiding concomitant use;

420        –    Temporarily discontinuing one of the interacting medicinal products;

421        –    Modifying the dosing regimen of one of the medicinal products;

422        –    Staggering drug administration (e.g., administer the investigational medicinal product at a
423             different time than a concomitant medicinal product);

424        –    Replacing one of the interacting drugs with a drug not expected to interact;

425        –    Implementing specific monitoring strategies (e.g., therapeutic drug monitoring, laboratory
426             testing).

427   Any proposed risk minimisation measures or alternative strategies for mitigating potential
428   gastrointestinal interactions should be documented in the Summary of Product Characteristics (SmPC)
429   in accordance with the EC SmPC guideline (2009).




      Guideline on the investigation of interactions in the gastrointestinal tract
      EMA/136069/2026                                                                                    Page 12/12

来源:EMA 官方医药监管信息 · ema.europa.eu